BackSangamo Therapeutics Overview

Sangamo Therapeutics Other Liabilities

Sangamo Therapeutics's other liabilities is $0.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00

Peer average

Loading

Sangamo Therapeutics Other Liabilities History

Loading

Sangamo Therapeutics vs. peers: Other Liabilities Comparison

Loading

Sangamo Therapeutics Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Sangamo Therapeutics (SGMO) FAQ

Sangamo Therapeutics (SGMO) currently reports a other liabilities of $0 as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Sangamo Therapeutics's other liabilities history and peer comparisons.

Sangamo Therapeutics's other liabilities changed from $0 to $0 (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sangamo Therapeutics reported $0 in other liabilities as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other liabilities of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sangamo Therapeutics, and consider following SGMO for alerts when major investors trade the stock.

Sangamo Therapeutics is classified in the Healthcare sector. On other liabilities, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SGMO with unrelated industries.